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PARAMETER LABOR4 TORIUM KLINIK DARI PRIA DEWASA PADA WAKTU 
UJI COBA KEMOPROFILAKSIS PRIUAKUIN DI IRLAN JA YA, INDONESIA 
Primakuin yang digunakan sebagai profilaksis malaria terbukti efektif dun diterima dengan baik 
oleh tubuh manusia yang normal terhadap aktivitas enzim 6 glukosa-6fosfat dehidrogenase (G-6PD). 
Pemeriksaan laboratoris klinik adalah bagian dari uji coba secara acak dengan kontrol plasebo 
dalam rangka mengevaluasi penggunaan primakuin sebagai profilaksis pada penduduk transmigran 
yang tidak kebal di Irian Jaya. 
Penelitian in; dilakukan terhadap 129 pria Jawa dewasa yang normal G-6PDnya. Pemeriksaan 
hematologi, fungsi hati dun ginjal, dun pemeriksaan limfosit dilakukan berulang kali selama waktu 
penelitian profilaksis dilakukan untuk menjamin keamanan dari sukarelawan tersebut dun mengawasi 
perubahan yang mungkin terjadi akibat obat profilaksis. 
Seperti yang diperkirakan, pengguna primakuin tidak menunjukkan gejala peningkatan 
methemoglobin yang kembali dalam batas normal setelah 7 hari pemberian dosis terakhir. Pada akhir 
penelitian (12 bulan profilaksis) nilai hematologi, fungsi hati dun ginjal, dun nilai limfosit dari 
kelompok primakuin sebanding dengan kelompok plasebo, dun berada dalam batas nilai normal untuk 
orang Indonesia. 
Hasil penelitian ini memberikan masukan adanya keluhan fisik yang sedikit dari sukarelawan 
pengguna profilaksis primakuin. Untuk membuktikan hasil penelitian ini dun mempersiapkan 
penggunaan secara umum primakuin untuk profilaksis malaria, perlu dilakukan uji coba lebih lanjut 
keamanan primakuin. Di Indonesia, primakuin tidak digunakan sebagai projilaksis dun laporan hasil 
penelitian ini hendaknya tidak ditafsirkan sebagai laporan keamanan dari primakuin. 
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INTRODUCTION 
Transmission of Plasmodium falciparunl 
and P. vlvax is intense throughout much of Irian 
Jaya, 1nd0nesia.l.~ Multi-dmg resistanl P. 
falciparum,"' and chloroquine-resistant P. 
 viva^?,^ are documented from the Arso region of 
this province and seriously threaten the health 
and development of nonimmune transmigrant 
communities. Cross-resistance and high cost 
limit the use of many currently available 
antimalarial drugs for prophylaxis. New dnlg 
development is a slow, expensive process with 
unprofitable returns from the populations that 
could most benefit from malaria prevention. 
Against these obstacles we re-evaluated 
primaquine as an immediately available, low 
cost alternative to chloroquine for malaria 
chemoprophylaxis. 
Primaquine has been the drug of choice for 
radical cure and terminal treatment of relapsing 
vivax malaria for nearly half a century. 
Primaquine is also gametocytocidal against all 
species of human malaria and its use has been 
advocated to reduce community transmission of 
falciparum malaria. Owing to its activity 
against the early liver stages of malaria 
parasites, primaquine has the potential to act as 
a causal prophylactic as well.lo." The Naval 
Medical Research Unit No. 2, in collaboration 
with the Infectious Diseases Research Center of 
the Indonesian Ministry of Health (Badan 
Penelitian dan Pengembangan Kesehatan, 
Departmen Kesehatan R.I.), and the Provincial 
Health Service, Jayapura, Irian Jaya, R.I. 
recently camed out chemoprophylaxis trials in 
Irian Jaya transmigration settlements that 
showed primaquine to be highly efficacious and 
well tolerated when used by non-pregnant 
individuals with normal glucose-6-phosphate 
dehydrogenase (G6PD) activity. The first of 
these trials took place in Arso X during 
December 1992 to April 1993 and compared an 
alternate day regimen of primaquine (0.5 mg 
baselkg) against weekly chloroquine for 
prevention of malaria in nonimmune Javanese 
trans migrant^.'^ The relative efficacy of* 
primaquine in this trial was 74% against P. 
fa/ciparum and 90% against P. v iva .  
Compared with people using chloroquine, there 
were significantly fewer physical complaints 
among people in the primaquine group and no 
signs of toxicity during the period of drug use. 
These encouraging results prompted a 
second, more detailed trial which sought to 
identify a more protective primaquine regimen 
and to evaluate the long-term tolerance of this 
drug. This second Irian Jaya trial randomized 
nonimmune adult male transmigrants of Arso 
XI to receive either daily primaquine, weekly 
chloroquine, or a daily placebo over a 12 month 
period. Chloroquine, the standard antimalarial 
provided to new transmigrants, was not 
significantly better than placebo in protecting 
against either falciparum or vivax malaria in 
this trial but daily primaquine provided >94% 
protection against falciparum and >90% 
protection against vivax malaria. Importantly, 
there was no difference between primaquine, 
placebo, and chloroquine in the occurrence of 
physical complaints and non-malarial illness." 
This trial offered an additional opportunity to 
confirm the tolerance and s,afety of extended 
primaquine use and significant efforts were 
made to deter any side effects. This paper 
reviews and compares the results of repeated 
clinical laboratory testing that was conducted. 
METHODS 
Study site and subjects 
The study took place in Arso XI, located 
50 km south of Jayapura, lrian Jaya. during the 
period July 1994 and March 1995. After 
providing informed written consent, 129 adult 
male Javanese volunteers were tested to confirm 
normal G6PD activity, curatively treated for 
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malaria, and randomized to receive either 
weekly chloroquine (300 mg base 1 time 
weekly), daily primaquine (0.5 mg basekg 
daily; 30 mg daily for men >55 kg) or a daily 
placebo over a 12 month period. The 
primaquine dosage in this trial was based on 
demonstrated safety and efficacy against the 
primaquine tolerant vivax malaria that occurs in 
the Indo-Pacific region.14 Drug was always 
given after a meal and consumption was 
witnessed. At 20 and 40 weeks of prophylaxis, 
laboratory test results and volunteer health were 
reviewed by committees for protection of human 
subjects to determine and approve continuation 
of the prophylaxis trial. Continuation was also 
contingent upon informed written consent of d l  
volunteers at both the 20 and 40 week decision 
points of prophylaxis. Physical complaints were 
recorded weekly by response to a list of 
questions read to each volunteer and by record 
of visits made to the on-site health clinic for any 
illness and injury. An exit questionaire was 
administered to all volunteers at the 52 week 
end point of prophylaxis. All medications and 
health needs were provided without cost. 
Volunteers were encouraged to self-report any 
illness and injury. 
Hematology 
Complete blood counts (hematocrit, 
hemoglobin, WBCs, granulocytes, lymphocytes 
-t monocytes, platelets) were conducted on all 
volunteers on day 0 and at 1, 10, 20, 40, and 52 
weeks of prophylaxis using automated CBC 
methodology (QBC Series Centrifugal Hemato- 
logy SystemR, Becton Dickinson, Sparks, MD). 
Methemoglobin testing by the Evelyn-Malloy 
spectrophotometric method" was performed on 
all subjects during week 50 of prophylaxis and 
7 days after the final dose of drug. 
Hepatic and renal function testing 
A cross-sectional sample of volunteers 
(30%) was tested repeatedly for hepatic and 
renal function (urcrt, b~lirubin, total protcin, 
albumin, creatinine, alanine aminotransferase 
[ALAT], aspartate aminotranferase [ASAT], 
and alkaline phosphatase [ALP]) on day 0 and 
at 10, 20, 40, and 52 weeks of prophylaxis 
according to recommended spectrophotometric 
methods (Boehringer Mannheim GmbH 
Diagnostics, Mannheim, Federal Republic of 
Germany). Dipstick urinalysis testing 
(Chemstrip-SR, Boehringer Mamheim 
Diagnostics, St. Louis, MO) was performed on 
all volunteers at the 52 week end point of 
prophylaxis. 
Lymphocyte function and s;bset composition 
A cross-sectional sample of volunteers 
(30%) was tested for lymphocyte function and 
subset composition at. 10 and 52 weeks of 
prophylaxis. Lymphocyte function was assessed 
by measuring the in vitro proliferative response 
of peripheral blood mononuclear cells (PBMC) 
against a panel of mitogens (PHA, PWM, 
ConA) and antigens (PPD, tetanus toxoid) 
according to current standard method~logy.'~ 
Lymphocyte subsets (total T cells, T helper, T 
effector, total B cells, NK cells, activated T 
cells) were enumerated by flow cytometry using 
Becton Dickinson SimultestR methodology and a 
flourescent activated cell sorter (Becton 
Dickinson Imn~unocytometry Systems, San Jose, 
CA). 
Data analysis 
Prophylaxis group test results were 
compared by one way analysis of variance and 
Bartlett's test for homogeneity of variance. 
Kruskal-Wallis non-parametric test was applied 
to data not normally distributed. Selected 
2-sample comparisons used Student's t-test for 
normally distributed data or the Mann-Whitney 
U test for data not normally distributed. 
Two-tailed p values arc reported. 
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RESULTS 
Within group comparisons between 
sampling times (baseline, 1, 10, and 20 weeks 
prophylaxis), and within time comparisons 
between groups (placebo, primaquine, 
chloroquine) detected only minor hematologic 
changes (Figure 1). Platelet counts were 
depressed during the first week in which the 
quinine-doxycycline-primaquine radical cure 
was administered and hematocritl hemoglobin 
levels increased from baseline in all groups. 
Statistical comparison between primaquine and 
placebo groups for hematologic, renal, and 
hepatic test values at the week 52 endpoint of 
prophylaxis identified a statistically significant 
increase over placebo in the mean value of only 
urea (Table 1). Despite this difference, all 
values for urea in the primaquine group were 
within the normal range. Comparison between 
baseline and endpoint values withn the 
primaquine group identified significant 
increases (p<0.05) over baseline in hemoglobin, 
% monocytes, serum protein, and ALP (Table 
2). This within group comparison revealed 
significant (p<0.002) reductions from baseline 
in % granulocytes, ASAT, and ALAT, but 
these changes did not fall outside the normal 
range (Table 2), and baseline measures may 
have been abnormally skewed by malaria 
infections (38%) at the time of enrollment. 
Endpoint qualitative urinalysis did not yield 
results indicative of differences between 
placebo, primaquine, and chloroquine groups 
(data not shown). 
Primaquine did induce asymptomatic 
methemoglobinernia. After. 50 weeks of 
prophylaxis, the mean percent methemoglobin 
in the primaquine group (5.8%, SD 2.9%) was 
sigxuficantly higher @<0.001) than in either 
chloroquine (0.7% SD 0.40/0), or placebo 
(1.2%, SD 0.7%) groups. Methemoglobin 
measures among primaquine users ranged from 
1.4% to 13% (Figure 2). Seven days after the 
final prophylactic dose of primaquine, mean 
percent methemoglobin for this group had 
declined significantly (pc0.000 1) to 2.4% (SD 
1.2%, range 0-4.5%). Methemoglobin level 
decreased in 27 of 30 subjects and the percent 
decline from week 50 values averaged 51% 
(range 2 1-100%) for the group (Figure 2). 
Laboratory assay of lymphocyte function 
and subset composition were intentionally 
delayed until week 10 of prophylaxis to achieve 
a more valid detection of prophylaxis-induced 
changes and to avoid possible confounding 
effects caused by malaria infection and radical 
curative therapy. Lymphocyte function in 
prophylaxis groups, as measured by 
proliferative response to mitogen (ConA, PHA, 
PWM) and antigen (PPD) stimulants is 
presented as geometric mean stimulation 
indices (GMSI) in Tables 3 and 4. Statistical 
comparison of GMSI values revealed no 
significant differences between primaquine, 
placebo, or chloroquine groups after 10 weeks 
of prophylaxis (Table 3). Lymphocyte function 
at the week 52 endpoint of prophylaxis, as 
measured by proliferative response to mitogen 
(PHA) and antigen (PPD, Tetanus toxoid) 
stimulants was also not sig~uficantly different 
among the three groups (Table 4). Lymphocyte 
subset composition (total T cells, total B cells, T 
helper, T effector, T helper:T effector ratio, NK 
cells, and activated T cells) was comparable 
among placebo, primaquine, and chloroquine 
groups at both the 10 and 52 week sampling 
points. Notably, the subset composition in each 
of the prophylaxis groups fell within a normal 
ethnic range derived from a larger (n=68) 
sample population of healthy Javanese- 
Sundanese males. 
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Table 1. Clinical laboratory test values for placebo and primaquine groups at the 52 week 
endpoint pf prophylaxis. 
* Values given as mean (SD) 
** Unpaired comparison by t-test or Mann-Whitney U-test. 
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Table 2. Clinical laboratory test values for daily primaquine group: 
Baseline vs. week 52 of prophylaxis. 
* Values given as mean (SD) 
** Unpaired comparison by t-test or Mann-Whitney U-test; nsd if P > 0.05.. 
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Figure 2. Paired comparison of methemoglobin levels in primaquine users (N=30) 
during week 50 prophylaxis and 7 days after ending prophylaxis. 
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Table 3. Lymphocyte function* among test groups after 10 weeks of chemoprophylaxis. 
* Geometric Mean Stimulation Index (cpm stimulated/cpm control) SD. 
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Table 4. Lymphocyte function* among test groups at the 52 week endpoint of chemoprophylaxis. 
* Geometric Mean Stimulation Index (cpm stimulatedlcpm control) + SD 
** Significantly different (pC0.05). 
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Table 5. Lymphocyte subset composition* among test groups after 10 weeks of 
chemoprophylaxis. 
* Mean percentages + SD 
** Healthy male Javanese-Sundanese (n=68). 
Description 
Bd. PeneUt. Kesehat. 23 (3) 1995 
Rae& 
fn=17) 
Primaquint: 
( ~ $ 5 )  
CD3 (Total T cell) 
CD19 (B cells) 
CD4 (T helperlinducer) 
CD8 (T suppressorlcytotoxic) 
CD4:CD8 ratio 
CD3lCD 16+CD56 (NK cells) 
CD31Anti-HLA-DR (Activated T cell) 
69.4 2 11.5 
13.3 + 4.2 
33.2 _+ 7.2 
39.3 2 8.8 
0.8850.24 
23.7 5 15.4 
21.4 2 10.2 
61.0 _+ 10.3 
13.2 f 5.0 
30.2 f 7.4 
43.0 + 8.0 
0.75 50 .33  
26.6 2 11.2 
21.0 2 6.4 
ChIorquine 
. fnZ14) . 
65.1 2 9.0 
13.9 2 4.3 
34.5 2 6.1 
38.9 2 5.7 
0.91 50.22 
21.2 4 8.7 
16.2 4 8.7 
* Mean percentages + SD 
** Healthy male Javanese-Sundanese (n=68). 
Table 6. Lymphocyte subset composition* among test groups at 52 week endpoint of 
chemoprophylaxis. 
-Normal Range+* 
<Indomsian) 
71.1 2 7.6 
12.3 2 3.7 
33.4 2 5.2 
37.3 2 6.1 
0.9420.23 
17.3 2 8.9 
14.9 5 7.6 
t 
Placebo Primaquine 
(nk2.7) 
69.8 29.1 
12.8 2 4.0 
36.6 5 6.0 
39.8 2 7.9 
0.9920.29 
26.3 5 14.1 
22.6 2 7.4 
hscri*on 
CD3 (Total T cell) 
CD19 (B cells) 
CD4 (T helperhnducer) 
CD8 (T suppressorlcytotoxic) 
CD4:CDR ratio 
CD3/CD16+CD56 (NK cells) 
CD3fAnti-HLA-DR (Activated T cell) 
( ~ t - 4 5 )  
70.2 58 .1  
14.7 f 5.8 
36.2 + 8.7 
38.9 2 8.8 
1.0420.51 
22.22 11.3 
20.5 2 12.7 
: CNaraquine 
. (n-9) 
No& Rangeg* 
fmdonesknj 
68.6 k7.2 
13.4 f 5.6 
35.4 + 4.8 
41.8 2 5.3 
0.91 50.22 
23.62 14.8 
19.0 If: 4.6 
61.0+ 10.3 
13.2 f 5.0 
30.2 f 7.4 
43.0 f 8.0 
0.75 20.33 
26 -65  11.2 
21.0 f 6.4 
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DISCUSSION 
Although primaquine has been in use for 
nearly 50 years, its protective efficacy and 
tolerance as a primary prophylactic against 
falcipanun and vivax malaria has only recently 
been evaluated under natural conditions of 
e~posure . '~ . '~  In these trials, primaquine was 
shown to be an effective, well-tolerated 
prophylactic with the advantage over other 
currently recommended antimalarial 
chemoprophylactics of low cost and immediate 
availability. Unlike most antimalarials which 
target the blood stages of malaria, primaquine is 
active against the primary liver stages and is 
probably not required after leaving the area of 
exposure." Furthermore, the rapid metabolism 
of primaquine, combined with its double action 
against both tissue schizont and gametocyte 
stages, would seemingly give malaria parasites 
very little chance for selection of resistance 
genotypes. 
There are a number of factors that must be 
realized and controlled for to ensure safe, 
efficacious use of primaquine for malaria 
prophylaxis: 1) Rapid metabolism of the drug 
requires that it be used on a daily or alternate 
day schedule, 2) Primaquine must only be used 
by individuals with proven, normal G6PD 
activity, 3) Prirnaquine has not yet been tested 
and proven safe for use during pregnancy, 4) It 
is necessary that each dose be taken with food to 
reduce the chances of stomach upset, and 5) 
Primaquine users should be aware of or 
monitored for signs and symptoms of 
methemoglobinemia. 10.11,'s.'9 Immune suppres- 
sion, a side effect of many antimalarial 
d ~ g s , ' ~ . ~ ~  was also considered to be a potential 
drawback of prirnaquine." 
The toxicology of primaquine in animals 
and man has been studied in depth and a large 
body of accumulated safety data supported our 
prophylaxis study. '7*22,23 Extended h l y  and 
alternate day use of primaquine has previously 
been shown to have no effect on hematologic, 
hepatic, and renal parameters that were 
measured in G6PD normal volunteers. 
Nevertheless, hemolytic reactions, 
hepatotoxicity, and methemoglobinemia have 
been manifestations of primaquine intoxication 
and were the primary focus of our testing 
program. The levels of asymptomatic 
methemoglobinemia detected after 12 months of 
primaquine use and the consistently normal 
measures obtained for hematologic, hepatic and 
renal function throughout the study period are 
signal findings that lend support for the safety 
and acceptability of this drug. It is notable that 
methemoglobin levels we detected during the 
twelfth month of primaquine prophylaxis were 
not significantly different from those reported 
for subjects given the usual 14 day treatment of 
primaquine at half the dosage we employed." 
The negative results we obtained in 
repeated tests of lymphocyte function and subset 
composition were not anticipated but are clearly 
ideal. Primaquine is credited with distortions of 
T cell populations and potential immune 
suppression. '0.11.20-23 This nonacute toxicity has 
not been well characterized and has not been a 
major concern given the current modality and 
low frequency of primaquine use, but over an 
extended period of prophylactic use, such a 
subtle, chronic effect on lymphocytes, if present, 
could have profound effects. Our negative 
results provide important new in vivo measures 
of long-term prophylaxis effect that document 
the immunologic safety of prirnaquine. Because 
we saw an unexpected trend toward 
primaquine-induced stimulation of lymphocyte 
response, this line of investigation is continuing 
with studies aimed at determining the 
interaction of primaquine prophylaxis and 
vaccination. 
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In summary, the collective clinical 
laboratory results of hematologic, hepatic, renal, 
and immune response testing herein reported 
provide compelling preliminary support for the 
safety of primaquine as a daily 
chemoprophylactic drug against malaria. 
Although cheap and available, primaquine is 
not approved or recommended for prophylactic 
use in Indonesia. This research report must not 
be construed as a definitive statement of 
primaquine safety or an official viewpoint of 
acceptance. It is important that further safety 
testing be conducted to verify the results we 
have obtained and to precede licensure of the 
drug for general use. 
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